ATHESIT M combines Sitagliptin 50 mg and Metformin Hydrochloride 500 mg to provide an effective treatment option for managing type 2 diabetes. Developed by Medathena Lifesciences, this formulation reflects our commitment to empowering health through affordable excellence in pharmaceuticals. Designed to support glycemic control with proven efficacy, ATHESIT M meets high-quality standards to ensure patient safety and therapeutic reliability. With our focus on accessible healthcare solutions, ATHESIT M is an essential addition to diabetes management therapies. Trust Medathena Lifesciences for advanced pharmaceutical formulations that prioritize both quality and affordability.